Gilead Sciences, Inc. (GILD) operating KPIs
GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026Score 11/30105% above fair value
$170.68+5.07 (+3.06%)
Close on Oct 30, 2026Market cap $211.64BP/E –Yield 1.85%
Gilead Sciences other Liver Disease (Harvoni, Vosevi, Viread, Hepcludex, Sovaldi & Livdelzi prior to Q1 2026) — Europe sales ($M) ($M)
Form 10-Q / 10-K Disaggregated Revenue Note & Form 8-K Product Sales Summary
Latest, Q2 2026
79
Period ended Jun 30, 2026
Change on a year earlier
+9.7%
72 in Q2 2025
History
14 quarters
Since Q1 2023
Sources
9
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Other Liver Disease (Harvoni, Vosevi, Viread, Hepcludex, Sovaldi & Livdelzi prior to Q1 2026) — Europe sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 79 | +9.7% | Form 10-Q (filed 2026-08-06) ↗ |
| Q1 2026 | Mar 31, 2026 | 78 | +2.6% | Form 10-Q (filed 2026-05-07) ↗ |
| Q4 2025 | Dec 31, 2025 | 97 | +79.6% | Form 10-K (filed 2026-02-24) ↗ |
| Q3 2025 | Sep 30, 2025 | 81 | +50.0% | Form 10-Q (filed 2025-11-07) ↗ |
| Q2 2025 | Jun 30, 2025 | 72 | +53.2% | Form 10-Q (filed 2026-08-06) ↗ |
| Q1 2025 | Mar 31, 2025 | 76 | +61.7% | Form 10-Q (filed 2026-05-07) ↗ |
| Q4 2024 | Dec 31, 2024 | 54 | +42.1% | Form 10-K (filed 2026-02-24) ↗ |
| Q3 2024 | Sep 30, 2024 | 54 | +63.6% | Form 10-Q (filed 2025-11-07) ↗ |
| Q2 2024 | Jun 30, 2024 | 47 | +27.0% | Form 10-Q (filed 2025-08-07) ↗ |
| Q1 2024 | Mar 31, 2024 | 47 | +14.6% | Form 10-Q (filed 2025-05-07) ↗ |
| Q4 2023 | Dec 31, 2023 | 38 | – | Form 10-K (filed 2026-02-24) ↗ |
| Q3 2023 | Sep 30, 2023 | 33 | – | Form 10-Q (filed 2024-11-12) ↗ |
| Q2 2023 | Jun 30, 2023 | 37 | – | Form 10-Q (filed 2024-08-08) ↗ |
| Q1 2023 | Mar 31, 2023 | 41 | – | Form 10-Q (filed 2024-05-08) ↗ |
Cite this data
StockData. (2026). Gilead Sciences Other Liver Disease (Harvoni, Vosevi, Viread, Hepcludex, Sovaldi & Livdelzi prior to Q1 2026) — Europe sales ($M) ($M), quarterly Q1 2023–Q2 2026 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/liver_other_eu
See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.